ClinicalTrials.gg

Program

ipsoprubart

Its studies are mostly in Lymphohistiocytosis, Hemophagocytic · Lymphoma, led by Electra Therapeutics.

Furthest: phase 3, since Jun 6, 20223 company-led studies, 2 open or runningNext primary completion: Mar 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Electra Therapeutics32 open or runningphase 3since Jun 6, 2022Jun 6, 2022Mar 2028phase 3 · NCT05416307

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 6, 2022First study: phase 3 study in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)First studyNCT05416307 · 156 planned · United States, Austria, Germany and more
  2. Sep 20, 2022Phase 1 study in Healthy VolunteersNCT05556863 · 91 enrolled · United States, Austria
  3. Mar 4, 2026Phase 1 study in LymphomaNCT07465835 · 84 planned · United States

Ahead

  1. Mar 2028Primary completion: phase 3 study in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)NCT05416307
  2. Jun 2028Primary completion: phase 1 study in LymphomaNCT07465835

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07465835Lymphoma · United States1RecruitingJun 202884
NCT05556863Healthy Volunteers · United States, Austria1CompletedNov 20, 202391
NCT05416307Secondary Hemophagocytic Lymphohistiocytosis (sHLH) · United States, Austria, Germany and more3RecruitingMar 2028156

How it is read

Names in the registry

  • “ELA026”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.